> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Forest Labs’ Avycaz
- URL: https://www.fdaweb.com/regulatory-review-period-for-forest-labs-avycaz/
- Published: 2018-01-18T12:00:00.000Z
- Updated: 2026-09-14T23:15:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140532

*Federal Register* notice: FDA has determined for patent extension purposes that the regulatory review period for Forest Laboratories’ Avycaz (ceftazidime pentahydrate and avibactam sodium) was 2,579 days. Of this time, 2,333 days occurred during the testing phase and 246 days occurred during the approval phase. The product is indicated for treating patients 18 years or older with the following infections caused by designated susceptible microorganisms: complicated intra-abdominal infections used in combination with metronidazole and complicated urinary tract infections. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-01-17/pdf/2018-00678.pdf?ref=fdaweb.com).